- Home
- MRM vs QNRX Comparison
MRM vs QNRX Comparison
Compare MRM & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | QNRX |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 9.2M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MRM | QNRX |
|---|---|---|
| Price | $0.95 | $4.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.3K | ★ 18.1K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $3.25 |
| 52 Week High | $4.45 | $41.80 |
Technical Indicators
Market Signals| Indicator | MRM | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 43.55 |
| Support Level | $0.92 | $4.09 |
| Resistance Level | $1.02 | $4.50 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 25.00 | 35.45 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.